Omnia and Intradigm Sign Deal for Nanomedicine Manufacture
News Mar 30, 2006
Omnia Biologics, Inc. and Intradigm Corporation have announced signing a master services agreement for Omnia to provide Intradigm with process development and cGMP manufacturing services. The deal will accelerate Intradigm's clinical development programs.
Intradigm is developing siRNA-derived therapeutics utilizing its proprietary nanomedicine technology and has led the advancement of siRNA from the test tube to a potent, tissue-targeted, systemically active therapeutic class of gene specific inhibitors.
"Dr. Woodle and his team have an impressive track record of success in developing first in class drug delivery systems in oncology," commented Dr. Dale VanderPutten, CEO, Omnia Biologics, Inc.
"Their application of this expertise to siRNA at Intradigm is a huge step forward for making nanotechnology practical in medicine."
"Intradigm's technology has begun to transcend traditional notions of small molecules versus biologics by incorporating aspects of each."
"The advantages of this technology over current therapeutic regimes are enormous and we are overjoyed that Intradigm chose Omnia to assist them in this important work."
"Omnia provides unique services for bridging pre-clinical and clinical manufacture. The breadth of their services is particularly important to small companies and those developing novel pharmaceuticals at pilot scale. We are very pleased to have their development assistance as we move toward the clinic," commented Dr. Martin Woodle, CSO, Intradigm Corporation.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.